Skip to main content

EDITORIAL article

Front. Pharmacol., 12 December 2022
Sec. Drug Metabolism and Transport
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.1063434

Editorial: Pharmacokinetic differences of drugs and their regulatory mechanisms under dual status including normal and diseased organism

www.frontiersin.orgZipeng Gong1,2,3*, www.frontiersin.orgJie Zhou1, www.frontiersin.orgLing Ye4, www.frontiersin.orgGuo Ma5, www.frontiersin.orgYanfang Xian6 and www.frontiersin.orgKaustubh Kulkarni7
  • 1State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, Guizhou Medical University, Guiyang, China
  • 2Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medical University, Zunyi, China
  • 3Guizhou Provincial Engineering Research Center for the Development and Application of Ethnic Medicine and TCM, Guizhou Medical University, Guiyang, China
  • 4NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
  • 5School of Pharmacy, Fudan University, Shanghai, China
  • 6School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, Hong Kong SAR, China
  • 7Boundless Bio Inc., San Diego, CA, United States

Dual status includes healthy state and pathological state. Pharmacokinetics (PKs) is a quantitative study of drug dynamic changes including the process of absorption, distribution, metabolism and excretion (ADME). In the course of innovative drug development, PK study is as important as pharmacodynamic and toxicological research in evaluating new drugs, which also plays a vital role in reducing the risks of new drug development existing in preclinical and clinical study. However, it is irrational that the current preclinical PK data largely come from healthy animals. Firstly, given that drugs are largely taken by patients, they are the ultimate consumers of drugs. Secondly, pathological body could lead to the change of drug metabolizing enzymes, drug transporters and intestinal microflora, which bring about the change of ADME of drugs and have adverse effect of the use of drugs in clinic. Therefore, carrying out the PK studies under pathological conditions would be more significant and closely related to clinic (Gong, et al., 2015).

Generally speaking, compared with the healthy state, the function of some tissues and organs of the body in the pathological conditions might be harmed. For instance, the expression and activity of drug metabolizing enzymes (DMEs) under diabetic conditions were altered (Chen et al., 2018). When the body was under rheumatoid arthritis conditions, the kind and amount of intestinal microflora were changed (Tajik et al., 2020). Moreover, the gap between adjacent intestinal cells in patients with irritable bowel syndrome was increased (Gong et al.). It is worth mentioning that these changes would alter the PK behavior of the drug. Also, inflammation could regulate the change of DMEs and transporters, and its possible mechanisms might largely involve inflammation-related signaling pathways and nuclear receptors, etc. (Wu et al., 2019), which led to changes in the PK process, efficacy and toxicity of drug. Therefore, the research on regulatory mechanisms causing the PK differences of drugs between healthy state and pathological state should be paid more attentions.

In the main frame of this Research Topic, 16 contributions have been published including but not limited to the following subjects: comparative PKs between healthy state and pathological state, the changes in the expression and activity of DMEs and transporters in pathological state, ADME/toxicity of drug and their regulatory mechanisms, drug-drug interactions mediated by nuclear receptors, DMEs and transporters based on the way of PKs, transcriptomics and metabolomics.

Wang et al. found that the Huangqi Liuyi decoction extract could be effective for improving the renal function when treating diabetic nephropathy. Moreover, the tissue distribution of six active ingredients in Huangqi Liuyi decoction extract could be affected by diabetic nephropathy state.

Zhang et al. compared PK of four main active ingredients of Liandan Xiaoyan Formula(LXF) in healthy and ulcerative colitis rats. They found that main active ingredients of LXF in the ulcerative colitis group had higher exposure than in the healthy group.

Liu et al. investigated the PK differences of three active diterpenoids of Rabdosia serra extract in healthy and concanavalin A-induced liver injury rats. They found that the PK process of three active diterpenoids in Rabdosia serra extract was influenced by liver injury.

Chen et al. found the compatibility of fuzi and ginseng could improve markedly the in vivo exposure of five bioactive ingredients including mesaconitine, benzoylaconitine, benzoylmesaconitine, benzoylhypaconitine, and songorine.

Chen et al. studied the PK behavior and main metabolites of anwulignan in mice. They identified that anwulignan might undergo the enterohepatic circulation. Moreover, seven metabolites were also identified, which mainly involved the demethylation, hydroxylation, dehydroxylation, and demethoxylation.

Liu et al. found Rehmanniae Radix (RR) displayed an inspiring antidiabetic effect by reducing the fasting blood glucose and insulin resistance, upregulating the mRNA and protein expressions of transient receptor potential vanilloid 1 (TRPV1), and downregulating mRNA expression of stearoyl-CoA desaturase 1 (SCD1). Therefore, induction of TRPV1 and inhibition of SCD1 by RR was possibly one of its antidiabetic mechanisms.

Ruan et al. evaluated an untargeted metabolomic strategy for discovering the biomarker of breast cancer, which would lay a base for discovering biomarker and investigating the disease mechanism.

Xu et al. elucidated the mechanism of Huang Qin decoction for treating the diabetic liver injury by the combination of metabolomics and network pharmacology.

Ke et al. investigated the mechanism of action of geniposide treating rheumatoid arthritis (RA) by employing metabonomic analysis of abnormal sphingolipid metabolism in RA synovial fibroblasts in hypoxia microenvironment and intervention of geniposide.

Chen et al. established a population pharmacokinetic (PPK) model for isoniazid (INH) and its major metabolite acetylisoniazid (AcINH) in healthy Chinese participants and tuberculosis patients and assessed the role of the NAT2 genotype on the transformation of INH to AcINH.

Wang et al. found JBP485 could save from imipenem nephrotoxicity in rabbits and human kidney 2 cells by increasing imipenem stability and reducing its intracellular accumulation by simultaneously inhibiting the renal organic anion transporters and dehydropeptidase-I.

Zhang et al. demonstrated that midazolam could ameliorate CCl4-induced acute liver injury and oxidative stress via activating the nuclear-factor erythroid 2-related factor 2 (Nrf2) signaling pathway.

Wang et al. evaluated the interaction of danshen and rivaroxaban by using the liver microsomes of rat and human. They found Danshen tablet could inhibit the metabolism of rivaroxaban due to its lipid-soluble ingredients such as dihydrotanshinone I could strongly inhibit the activity of CYP3A and CYP2J.

Xie et al. summarized the solubility, permeability, molecular structure and molecular weight characteristics of various natural medicines that affected cerebral metabolism (NMCs), and reviewed drug delivery systems that enhanced the PK and pharmacodynamic features of NMCs. Moreover, the structure-based in vivo metabolic reactions regulated by DMEs and metabolites of NMCs were also reviewed.

Yu et al. identified new platelet-derived growth factor receptor α (PDGFRA) inhibitors from traditional Chinese medicine (TCM) in silico and verified their effects of targeting PDGFRA and radioiodine uptake, which could provide a potential drug lead for developing a new radioiodine-refractory thyroid cancer therapy.

Li et al. summarized the research progress of the material composition, pharmaceutical production, clinical application and pharmacology mechanism of various TCM film agents, which might provide a comprehensive reference for further development and utilization of TCM film agents.

Therefore, given that drugs are largely taken by patients, the current topic focused mainly on PK differences of drugs and their regulatory mechanisms under healthy state and pathological state, which could provide reference and ideas for individualized safety and effective drug use, and optimizing the drug evaluation system based on disease states.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

This study was funded by the National Natural Science Foundation of China (Nos. 81860734 and 82160789), Guiyang Science and Technology Bureau ((2021) 43-12), the Excellent Young Talents Plan of Guizhou Medical University (No. 2022-104), the project of Key Laboratory of Basic Pharmacology of Ministry of Education, Zunyi Medicial University (KY (2022)394) and University Student Innovation and Entrepreneurship Project of Guizhou Province (No. S202110660046).

Acknowledgments

We would like to express our gratitude to all the authors for the valuable sharing of their findings and opinions.

Conflicts of interest

KK was employed by the Company Boundless Bio Inc.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Chen, F., Li, D. Y., Zhang, B., Sun, J. Y., Sun, F., Ji, X., et al. (2018). Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: What is the potential clinical significance? Drug Metab. Rev. 50 (3), 369–397. doi:10.1080/03602532.2018.1497645

PubMed Abstract | CrossRef Full Text | Google Scholar

Gong, Z. P., Chen, Y., Zhang, R. J., Yang, Q., and Zhu, X. X. (2015). Advances on pharmacokinetics of traditional Chinese medicine under disease states. China. J. Chin. Mat. Med. 40 (02), 169–173. doi:10.4268/cjcmm20150202

CrossRef Full Text | Google Scholar

Gong, Z. P., Yang, Q., Wang, Y. J., Weng, X. G., Li, Y., Dong, Y., et al. (2022). Pharmacokinetic differences of wuji pill components in normal and chronic visceral hypersensitivity irritable bowel syndrome rats attributable to changes in tight junction and transporters. Front. Pharmacol. 13, 948678. doi:10.3389/fphar.2022.948678

PubMed Abstract | CrossRef Full Text | Google Scholar

Tajik, N., Frech, M., Schulz, O., Schälter, F., Lucas, S., Azizov, V., et al. (2020). Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat. Commun. 11 (1), 1995. doi:10.1038/s41467-020-15831-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Wu, K. C., and Lin, C. J. (2019). The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.fiammation: Evidences in infiammatory diseases and age-related disorders. J. Food Drug Anal. 27 (1), 48–59. doi:10.1016/j.jfda.2018.11.005

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: dual status, pharmacokinetic differences, drug metabolizing enzymes, transporters, nuclear receptors, pharmacokinetic-pharmacodynamic model

Citation: Gong Z, Zhou J, Ye L, Ma G, Xian Y and Kulkarni K (2022) Editorial: Pharmacokinetic differences of drugs and their regulatory mechanisms under dual status including normal and diseased organism. Front. Pharmacol. 13:1063434. doi: 10.3389/fphar.2022.1063434

Received: 07 October 2022; Accepted: 05 December 2022;
Published: 12 December 2022.

Edited and reviewed by:

Lin-Lin Chen, Hubei University of Chinese Medicine, China

Copyright © 2022 Gong, Zhou, Ye, Ma, Xian and Kulkarni. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zipeng Gong, gzp4012607@126.com

Download